NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Lumos Pharma
Lumos Pharma
Lumos Pharma
Masonic Cancer Center, University of Minnesota
H. Lee Moffitt Cancer Center and Research Institute